ACRS: Aclaris Consensus Target
Visualizing the market price of Aclaris Therapeutics (ACRS) helps assess the impact of alliances with biotech centers that accelerate the release of anti-inflammatory agents. The current indicator is 10.96. Management's strategy relies on portfolio optimization to combat dermatological pathologies. Business stability is supported by loyal immunologists and recruited FDA regulatory specialists, ensuring the high-quality development of the pipeline.
Analytical breakdowns for Aclaris (ACRS)
- stock value and consensus price forecast:
- market capitalization information:
- book value of equity indicators:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Aclaris Therapeutics|ACRS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Aclaris Therapeutics, Inc|ACRS - Company Aggregate Debts|Debts to Book Capitalization Aclaris|ACRS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Aclaris Therapeutics|Quick Liquidity Indicator aclaristx.com
- earnings and valuation multiples information:
ACRS - Net Profit|Projected Future Earnings Aclaris Therapeutics|ACRS - Price to Earnings Ratio|Future Price to Earnings Multiple Aclaris Therapeutics Inc.|ACRS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Aclaris|ACRS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Aclaris Therapeutics|ACRS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months aclaristx.com|ACRS - Net earnings per share growth this year|Earnings growth forecast for next year Aclaris Therapeutics
General company analysis:ACRS aclaristx.com
Strategic partnerships of Aclaris Therapeutics (ACRS) in the field of kinase inhibitors create scientific synergy, directly influencing market expectations regarding the value of future drugs. An analysis of the current consensus valuation of the stock reveals a gap between financial reporting and market reaction, measuring capital density and the risk of overpaying for the asset, taking into account the dynamics of government subsidies and the issuer's tax regime.
Competitors of Aclaris Therapeutics
Analyst Consensus Forecast argenx.com (ARGX)|Analyst Consensus Forecast BNTX (BioNTech)|ABVX - Consensus Target|ADMA - Price Target Chart|Fair Value Consensus PTGX (Protagonist Corp)|Immunovant, Inc. (IMVT) - Price Target Chart|KNSA - Analyst Median Target|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|KYTX - Analyst Consensus Forecast|TLSA: Analyst Consensus Forecast|Consensus Target cabalettabio.com|Price Target Chart Ventyx Biosciences, Inc.|Price Target Chart THTX|Analyst Consensus Forecast AVTX|Analyst Consensus Forecast Eledon Pharmaceuticals, Inc (ELDN)|Price Target Chart Agenus AGEN|Fair Value Consensus CLYM|Zura Bio Limited - Analyst Consensus Forecast|Analyst Median Target aTyr Pharma Inc ATYR|adagene.com (ADAG) - Price Target Chart|IMA - Analyst Median Target|Consensus Target STTK|EQ: Fair Value Consensus|Consensus Target CNTB (Connect Biopharma)|Analyst Forecast Prices IMUX|Analyst Consensus Forecast ATRA (Atara Bio)|Fair Value Consensus IFRX|X4 Pharmaceuticals - Analyst Consensus Forecast|Average Forecast Price Adicet Bio|celularity.com (CELU) - Price Target Chart|INmune Bio Inc - Fair Value Consensus|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Kezar Life Sciences Inc|Price Target Chart SAB Biotherapeutics (SABS)|AKTX: Forecast Levels Chart|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Average Forecast Price|GOVX: Consensus Target|EDSA - Analyst Consensus Forecast|IBIO (iBio, Inc.) - Consensus Target|CARM: Analyst Forecast Prices|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Bolt Bio (BOLT) - Analyst Median Target|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Price Target Chart AIM ImmunoTech AIM|Analyst Median Target Aditxt Inc. (ADTX)|GRI Bio - Analyst Consensus Forecast|XRTX - Analyst Consensus Forecast|HIND: Analyst Consensus Forecast|Consensus Target Revelation Biosciences Corp|Price Target Chart Indaptus Therapeutics|SCNI: Fair Value Consensus|Price Target Chart CalciMedica, Inc. (CALI)|Analyst Median Target affimed.com|Price Target Chart Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Forecast Levels Chart|IGM Bio - Analyst Consensus Forecast|Fair Value Consensus ITOS (iteostherapeutics.com)|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
